College of Pharmaceutical Sciences & College of Chinese Medicine, Southwest University, Chongqing, 400715, People's Republic of China.
Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, 445000, People's Republic of China.
Drug Des Devel Ther. 2022 Jan 25;16:279-296. doi: 10.2147/DDDT.S343928. eCollection 2022.
Catalpol is the main active component of Rehmannia glutinosa, which has a variety of pharmacological activities, including anti-inflammatory and anti-oxidative effects. This study investigates the feasibility of catalpol intranasal administration and its protective effect on acute cerebral ischemia in rats via anti-oxidative and anti-apoptotic mechanisms.
This study investigates the method of catalpol intranasal administration to evaluate the nasal mucosal toxicity, brain targeting and pharmacokinetics of catalpol. The protective effect of catalpol of intranasal administration on stroke-induced brain injury in rats and its mechanisms on oxidative stress pathway Nrf2/HO-1 and apoptosis were also investigated using middle cerebral artery occlusion (MCAO).
The results showed that catalpol intranasal administration was safe and feasible with no hemolysis, no bad effect on the maxillary ciliary movement of bullfrog. After intranasal administration, the brain targeting index (DTI) of catalpol was greater than 1, which indicated that catalpol had good brain targeting after intranasal administration. The bioavailability of catalpol administered intranasally was higher than that of in plasma. In MACO model, catalpol intranasal administration could significantly reduce cerebral infarction volume, neurological dysfunction and brain edema. In addition, catalpol intranasal administration can also reduce the brain cell's occurrence of apoptosis, promote the expression of Bcl-2 protein and inhibit the expression of Bax protein, reduce oxidative stress damage via up-regulating expression of Nrf2 and HO-1, increasing the activities of SOD and decreasing the activities of MDA.
Collectively, catalpol intranasal administration has good safety, stability and brain targeting. It can effectively protect the brain injury of the rat model of acute cerebral ischemia and provide the possibility of drug administration in the acute stage of cerebral ischemia, especially before entering the hospital.
梓醇是地黄的主要活性成分,具有多种药理活性,包括抗炎和抗氧化作用。本研究通过抗氧化和抗细胞凋亡机制,探讨梓醇经鼻腔给药的可行性及其对大鼠急性脑缺血的保护作用。
本研究探讨了梓醇经鼻腔给药的方法,以评估梓醇的鼻腔黏膜毒性、脑靶向和药代动力学。通过大脑中动脉闭塞(MCAO),还研究了梓醇经鼻腔给药对大鼠中风引起的脑损伤的保护作用及其对氧化应激通路 Nrf2/HO-1 和细胞凋亡的机制。
结果表明,梓醇经鼻腔给药安全可行,无溶血,对牛蛙上颌纤毛运动无不良影响。经鼻腔给药后,梓醇的脑靶向指数(DTI)大于 1,表明梓醇经鼻腔给药后具有良好的脑靶向性。经鼻腔给予梓醇的生物利用度高于血浆中的生物利用度。在 MACO 模型中,梓醇经鼻腔给药可显著减少脑梗死体积、神经功能障碍和脑水肿。此外,梓醇经鼻腔给药还可以减少脑细胞凋亡的发生,促进 Bcl-2 蛋白的表达,抑制 Bax 蛋白的表达,通过上调 Nrf2 和 HO-1 的表达,增加 SOD 的活性,降低 MDA 的活性,减轻氧化应激损伤。
综上所述,梓醇经鼻腔给药具有良好的安全性、稳定性和脑靶向性。它可以有效保护急性脑缺血大鼠模型的脑损伤,并为脑缺血急性期,特别是在入院前提供药物治疗的可能性。